File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Do statins reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis B?

TitleDo statins reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis B?
Authors
Issue Date2013
PublisherAME Publishing Company. The Journal's web site is located at http://www.thehbsn.org/
Citation
Hepatobiliary Surgery and Nutrition, 2013, v. 2 n. 1, p. 34-36 How to Cite?
AbstractIn subjects with chronic hepatitis B (CHB), the lifetime risk of developing hepatocellular carcinoma (HCC) is estimated to be 25-37 times compared to non-infected subjects. The process of hepatocarcinogenesis is complex and involves well-documented host, viral, and environmental risk factors. The most important risks include host factors such as older age, male gender, the presence of cirrhosis, and viral factors such as the viral load, genotype, and the presence of basal core promoter mutations. To date, antiviral therapy is the only intervention demonstrated to significantly reduce the risk of HCC development in CHB patients. Although oxidative stress has been implicated in cancer development, there is no established benefit shown from treatment with antioxidizing agents such as silymarin, green tea, and vitamin E.
Persistent Identifierhttp://hdl.handle.net/10722/186062
ISSN

 

DC FieldValueLanguage
dc.contributor.authorFung, Jen_US
dc.contributor.authorLai, CLen_US
dc.contributor.authorYuen, MFen_US
dc.contributor.authorNg, IOLen_US
dc.date.accessioned2013-08-20T11:50:26Z-
dc.date.available2013-08-20T11:50:26Z-
dc.date.issued2013en_US
dc.identifier.citationHepatobiliary Surgery and Nutrition, 2013, v. 2 n. 1, p. 34-36en_US
dc.identifier.issn2304-3881-
dc.identifier.urihttp://hdl.handle.net/10722/186062-
dc.description.abstractIn subjects with chronic hepatitis B (CHB), the lifetime risk of developing hepatocellular carcinoma (HCC) is estimated to be 25-37 times compared to non-infected subjects. The process of hepatocarcinogenesis is complex and involves well-documented host, viral, and environmental risk factors. The most important risks include host factors such as older age, male gender, the presence of cirrhosis, and viral factors such as the viral load, genotype, and the presence of basal core promoter mutations. To date, antiviral therapy is the only intervention demonstrated to significantly reduce the risk of HCC development in CHB patients. Although oxidative stress has been implicated in cancer development, there is no established benefit shown from treatment with antioxidizing agents such as silymarin, green tea, and vitamin E.-
dc.languageengen_US
dc.publisherAME Publishing Company. The Journal's web site is located at http://www.thehbsn.org/-
dc.relation.ispartofHepatobiliary Surgery and Nutritionen_US
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.titleDo statins reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis B?en_US
dc.typeArticleen_US
dc.identifier.emailFung, J: jfung@hkucc.hku.hken_US
dc.identifier.emailLai, CL: hrmelcl@hku.hken_US
dc.identifier.emailYuen, MF: mfyuen@hku.hken_US
dc.identifier.emailNg, IOL: iolng@hku.hken_US
dc.identifier.authorityFung, JYY=rp00518en_US
dc.identifier.authorityYuen, RMF=rp00479en_US
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.3978/j.issn.2304-3881.2012.10.04-
dc.identifier.hkuros220779en_US
dc.identifier.volume2en_US
dc.identifier.issue1en_US
dc.identifier.spage34en_US
dc.identifier.epage36en_US
dc.publisher.placeHong Kong-
dc.customcontrol.immutablecsl 140226-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats